Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Physicians Interactive

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

Merck to donate Sudan Ebola virus vaccine to International AIDS Vaccine Initiative

Around 50,000 doses are expected to be provided for further clinical research use

- PMLiVE

Merck’s Prevymis shows promise in phase 3 cytomegalovirus disease prevention trial

The drug demonstrated non-inferior efficacy compared to standard of care valganciclovir

- PMLiVE

Merck and Bill & Melinda Gates Institute sign licensing agreement for tuberculosis candidates

The non-profit will determine their potential for inclusion in new affordable treatment regimens

- PMLiVE

Merck and Moderna to jointly develop personalised cancer vaccine in $250m deal

The vaccine is currently being evaluated as a treatment for high-risk melanoma patients

- PMLiVE

Merck to initiate phase 3 HIV-1 clinical programme with a lower dose of islatravir

A phase 2 study evaluating islatravir with Gilead’s lenacapavir will also resume with the lower dose

- PMLiVE

Organon buys Forendo in $1bn deal

Forendo purchase bolsters Organon’s pipeline with candidates in endometriosis and polycystic ovarian syndrome

- PMLiVE

Merck’s $11.5bn acquisition of Acceleron delayed

Merck’s acquisition of Acceleron will take longer than expected as it refiles its paperwork, giving the FTC more time for review and itself more time to sell the deal to...

- PMLiVE

Merck’s COVID-19 antiviral under review in Europe by EMA

Molnupiravir could be the first oral antiviral treatment for COVID-19 in Europe for patients at risk of severe disease

- PMLiVE

Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’

Sales grew by 19% in the second quarter as key products begin to recover from the impact of the pandemic

- PMLiVE

Keytruda scores a win in treating early-stage breast cancer pre- and post-surgery

The FDA had previously rejected a supplemental biologics licence application in this indication

- PMLiVE

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links